Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors

British Journal of Pharmacology

Volumn 173, Issue 5, 2016, Pages 815-825

  Hind, William H ^a   England, Timothy J ^a   O'Sullivan, Saoirse E ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; GLUCOSE; LACTATE DEHYDROGENASE; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SEROTONIN 1A RECEPTOR; VANILLOID RECEPTOR 1; VASCULAR CELL ADHESION MOLECULE 1; NEUROPROTECTIVE AGENT; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; ASTROCYTE; BIOASSAY; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CAPILLARY ENDOTHELIAL CELL; CELL ADHESION; CELL DAMAGE; COCULTURE; CONTROLLED STUDY; ELECTRIC RESISTANCE; ENZYME RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROLOGICAL AND SENSORIAL PROCEDURES; NEUROPROTECTION; OXYGEN GLUCOSE DEPRIVATION; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION; TRANSEPITHELIAL RESISTANCE; CELL CULTURE; CELL HYPOXIA; DEFICIENCY; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; PERMEABILITY;

ASTROCYTES; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CANNABIDIOL; CELL HYPOXIA; CELLS, CULTURED; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; GLUCOSE; HUMANS; NEUROPROTECTIVE AGENTS; PERMEABILITY; PPAR GAMMA; RECEPTOR, SEROTONIN, 5-HT1A; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84958787193     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13368     Document Type: Article

References (45)

1. Abbott NJ, (2002). Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 200: 629-638.
2. Abbott NJ, Ronnback L, Hansson E, (2006). Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7: 41-53.
3. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al,. (2013a). The Concise Guide to PHARMACOLOGY 2013/14:Ion channels. Br J Pharmacol 170: 1607-1651.
4. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al,. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
5. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al,. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
6. Alhamoruni A, Lee AC, Wright KL, Larvin M, O'Sullivan SE, (2010). Pharmacological effects of cannabinoids on the Caco-2 cell culture model of intestinal permeability. J Pharmacol Exp Ther 335: 92-102.
7. Alhamoruni A, Wright KL, Larvin M, O'Sullivan SE, (2012). Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. Br J Pharmacol 165: 2598-2610.
8. Allen CL, Bayraktutan U, (2009). Antioxidants attenuate hyperglycaemia-mediated brain endothelial cell dysfunction and blood-brain barrier hyperpermeability. Diabetes Obes Metab 11: 480-490.
9. Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA, (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 6: 237-249.
10. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al,. (2001). Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852.
11. Castillo A, Tolon MR, Fernandez-Ruiz J, Romero J, Martinez-Orgado J, (2010). The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis 37: 434-440.
12. Ceulemans AG, Zgavc T, Kooijman R, Hachimi-Idrissi S, Sarre S, Michotte Y, (2010). The dual role of the neuroinflammatory response after ischemic stroke: Modulatory effects of hypothermia. J Neuroinflammation 7: 74.
13. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI, (2006). Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 168: 235-244.
14. England TJ, Hind WH, Rasid NA, O'Sullivan SE, (2015). Cannabinoids in experimental stroke: A systematic review and meta-analysis. J Cereb Blood Flow Metab 35: 348-358. Epub 2014 Dec 10. Review.
15. Fernandez-Ruiz J, Sagredo O, Pazos MR, Garcia C, Pertwee R, Mechoulam R, et al,. (2013). Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 75: 323-333.
16. Gertz K, Kronenberg G, Kalin RE, Baldinger T, Werner C, Balkaya M, et al,. (2012). Essential role of interleukin-6 in post-stroke angiogenesis. Brain 135: 1964-1980.
17. Green AR, Shuaib A, (2006). Therapeutic strategies for the treatment of stroke. Drug Discov Today 11: 681-693.
18. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R, (1996). 'Malignant' middle cerebral artery territory infarction: Clinical course and prognostic signs. Arch Neurol 53: 309-315.
19. Hayakawa K, Mishima K, Fujiwara M, (2010). Therapeutic potential of non-psychotropic cannabidiol in ischemic stroke. Pharmaceuticals 3: 2197-2212.
20. Hind WH, Tufarelli C, Neophytou M, Anderson SI, England TJ, O'Sullivan SE, (2015). Endocannabinoids modulate human blood-brain barrier permeability in vitro. Br J Pharmacol 172: 3015-3027.
21. Jander S, Pohl J, Gillen C, Schroeter M, Stoll G, (1996). Vascular cell adhesion molecule-1 mRNA is expressed in immune-mediated and ischemic injury of the rat nervous system. J Neuroimmunol 70: 75-80.
22. Kitagawa K, (2007). CREB and cAMP response element-mediated gene expression in the ischemic brain. FEBS J 274: 3210-3217.
23. Kotake D, Hirasawa N, (2013). Activation of a retinoic acid receptor pathway by thiazolidinediones induces production of vascular endothelial growth factor/vascular permeability factor in OP9 adipocytes. Eur J Pharmacol 707: 95-103.
24. Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM, (2015) Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor. Br J Pharmacol. doi: 10.1111/bph.13250 [Epub ahead of print] PubMed PMID: 26218440.
25. Lo EH, Dalkara T, Moskowitz MA, (2003). Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4: 399-415.
26. Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, et al,. (2006). Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 97: 435-448.
27. McPartland JM, Duncan M, Di Marzo V, Pertwee RG, (2015). Are cannabidiol and Δ(9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172: 737-753.
28. Mecha M, Feliu A, Inigo PM, Mestre L, Carrillo-Salinas FJ, Guaza C, (2013). Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors. Neurobiol Dis 59: 141-150.
29. Mestre L, Docagne F, Correa F, Loria F, Hernangomez M, Borrell J, et al,. (2009). A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules. Mol Cell Neurosci 40: 258-266.
30. Miao Y, Liao JK, (2014). Potential serum biomarkers in the pathophysiological processes of stroke. Expert Rev Neurother 14: 173-185.
31. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW, (2006). 1,026 experimental treatments in acute stroke. Ann Neurol 59: 467-477.
32. O'Sullivan SE, Kendall DA, Randall MD, (2009). Time-dependent vascular effects of endocannabinoids mediated by peroxisome proliferator-activated receptor gamma (PPARgamma). PPAR Res 2009: 425289.
33. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al,. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: An expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
34. Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC, (1998). Complex pharmacology of natural cannabinoids: Evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63: PL1-PL6.
35. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Drel VR, et al,. (2007). Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol 293: H610-H619.
36. Ramirez SH, Heilman D, Morsey B, Potula R, Haorah J, Persidsky Y, (2008). Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes. J Immunol 180: 1854-1865.
37. Schoch HJ, Fischer S, Marti HH, (2002). Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 125: 2549-2557.
38. Shiavon AP, Soares LM, Bonato JM, Milani H, Guimaraes FS, Weffort de Oliveira RM, (2014). Protective Effects of Cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Neurotox Res 26: 307-316.
39. Song HY, Ju SM, Seo WY, Goh AR, Lee JK, Bae YS, et al,. (2011). Nox2-based NADPH oxidase mediates HIV-1 Tat-induced up-regulation of VCAM-1/ICAM-1 and subsequent monocyte adhesion in human astrocytes. Free Radic Biol Med 50: 576-584.
40. Srivastava K, Shao B, Bayraktutan U, (2013). PKC-beta exacerbates in vitro brain barrier damage in hyperglycemic settings via regulation of RhoA/Rho-kinase/MLC2 pathway. J Cereb Blood Flow Metab 33: 1928-1936.
41. Vanden Berghe W, Vermeulen L, De Wilde G, De Bosscher K, Boone E, Haegeman G, (2000). Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol 60: 1185-1195.
42. Wen AY, Sakamoto KM, Miller LS, (2010). The role of the transcription factor CREB in immune function. J Immunol 185: 6413-6419.
43. Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG, (2006). Microglia potentiate damage to blood-brain barrier constituents: Improvement by minocycline in vivo and in vitro. Stroke 37: 1087-1093.
44. Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ, (2002). Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med Res Rev 22: 146-167.
45. Zhang ZG, Zhang L, Tsang W, Soltanian-Zadeh H, Morris D, Zhang R, et al,. (2002). Correlation of VEGF and angiopoietin expression with disruption of blood-brain barrier and angiogenesis after focal cerebral ischemia. J Cereb Blood Flow Metab 22: 379-392.